Next |
home / stock / eyen / eyen message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: EYEN 18% v774K c2.48 f34,2M H2.49 20dm@1.74 ML1.52 | znewcar1 | investorshangout | 09/08/2022 10:06:25 PM |
znewcar1: EYEN 25% v1,6M c2.04 f34,2M H2.07 ML1.52 | znewcar1 | investorshangout | 09/02/2022 12:01:14 AM |
$EYEN -- | honest dave | investorshub | 10/26/2021 1:36:42 PM |
AviseAnalytics: 5 BIOTECH STOCKS INSIDERS ARE BUYING! Insider selling or buying cannot be the sole i | AviseAnalytics | investorshangout | 09/01/2021 10:42:36 AM |
EYEN now trading options!!!! | jdlamont | investorshub | 03/15/2021 7:20:34 PM |
EYEN now trading options!!!! | jdlamont | investorshub | 03/15/2021 7:20:17 PM |
Good NEWS | beambe | investorshub | 08/21/2020 2:11:03 PM |
good Volume | beambe | investorshub | 08/19/2020 2:01:58 PM |
https://eyenovia.com/about-2019/ | beambe | investorshub | 08/18/2020 6:35:47 PM |
znewcar1: EYEN 38% v60,7M c5.03 f19,7M preMH8.43 then fell S@4.8 | znewcar1 | investorshangout | 08/11/2020 9:00:45 PM |
* * $EYEN Video Chart 08-11-2020 * * | ClayTrader | investorshub | 08/11/2020 7:57:27 PM |
good Volume | beambe | investorshub | 08/11/2020 7:37:11 PM |
$OCGN - .62 orphan FDA approvals | breezy1 | investorshub | 08/11/2020 1:49:06 PM |
Eyenovia and Arctic Vision Announce Exclusive Collaboration and | crudeoil24 | investorshub | 08/11/2020 12:16:56 PM |
next $10 stock soon | BioSpecialist | investorshub | 06/17/2020 4:42:06 PM |
STRONG BUY | BioSpecialist | investorshub | 06/17/2020 2:34:43 PM |
EYEN = MC $60 Million /NDA submission for | BioSpecialist | investorshub | 06/16/2020 7:28:21 PM |
anyone who sees the video of the kid | jdlamont | investorshub | 01/11/2020 2:24:37 AM |
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY | ADVFN_bioking | investorshub | 12/17/2019 3:47:58 PM |
looks like next breakout about to start | ADVFN_bioking | investorshub | 12/17/2019 3:37:13 PM |
News, Short Squeeze, Breakout and More Instantly...
Eyenovia Inc. Company Name:
EYEN Stock Symbol:
NASDAQ Market:
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalm...
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025 Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobe...
Company to demonstrate Mydcombi™ and Avenova ® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms ...